Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
Sep 22, 2025 | Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs, Savings, Transparency
Across the country, more employers are moving away from traditional pharmacy benefit managers in favor of transparent solutions. MedBen Rx has been ahead of this trend for years, offering clients clarity and lower costs that others are only now beginning to seek. A...
Sep 9, 2025 | Genomics, Lifestyle, MedBen Rx, Nutrigenomics, Wellness
Nutrigenomics is also known as “personalized nutrition” because it considers an individual’s unique dietary needs as well as their health status and lifestyle. Nutrigenomic testing through MedBen Rx brings this emerging science into the workplace,...
Aug 25, 2025 | Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Rx Costs, Transparency
A new paper from the American Medical Association (AMA) has found that the pharmacy benefit manager (PBM) marketplace remains highly concentrated, with just a few major players controlling most of the activity. Many of these PBMs are vertically integrated with health...
Aug 11, 2025 | Benefits preservation, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
Specialty medications continue to drive a disproportionate share of prescription drug costs – often accounting for 60% or more of a pharmacy plan’s total spend. MedBen Rx’s Benefit Preservation helps plans manage these expenses without compromising care by...
Jul 29, 2025 | biologics, Biosimilars, Cost Savings, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
